tiprankstipranks
Blurbs

Analysts’ Top Healthcare Picks: CTI BioPharma (CTIC), Mustang Bio (MBIO)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CTI BioPharma (CTICResearch Report), Mustang Bio (MBIOResearch Report) and Exagen (XGNResearch Report) with bullish sentiments.

CTI BioPharma (CTIC)

In a report released today, Robert Hazlett from BTIG reiterated a Buy rating on CTI BioPharma, with a price target of $10.00. The company’s shares closed last Thursday at $4.66, close to its 52-week high of $4.87.

According to TipRanks.com, Hazlett is a 3-star analyst with an average return of 4.9% and a 37.7% success rate. Hazlett covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Eiger Biopharmaceuticals, and TRACON Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for CTI BioPharma with a $8.12 average price target.

See the top stocks recommended by analysts >>

Mustang Bio (MBIO)

In a report released yesterday, Justin Zelin from BTIG maintained a Buy rating on Mustang Bio, with a price target of $11.00. The company’s shares closed last Thursday at $1.09, close to its 52-week low of $0.72.

According to TipRanks.com, Zelin has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -13.0% and a 27.1% success rate. Zelin covers the Healthcare sector, focusing on stocks such as Poseida Therapeutics, Viking Therapeutics, and Surface Oncology.

Mustang Bio has an analyst consensus of Strong Buy, with a price target consensus of $8.00, a 724.7% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $7.00 price target.

Exagen (XGN)

In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Exagen, with a price target of $15.00. The company’s shares closed last Thursday at $8.30, close to its 52-week low of $6.84.

According to TipRanks.com, Massaro is a 4-star analyst with an average return of 8.7% and a 48.8% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Ginkgo Bioworks Holdings, Accelerate Diagnostics, and Talis Biomedical.

Currently, the analyst consensus on Exagen is a Strong Buy with an average price target of $16.67, a 90.3% upside from current levels. In a report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $19.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CTIC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed